Cytokinetics Inc CYTK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Cytokinetics to Host Investor & Analyst Day on October 16, 2024
-
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the HFSA Annual Scientific Meeting
-
Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific Sessions
-
Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant Program
-
Cytokinetics Announces Upcoming Presentations at the HCMS Scientific Sessions and the HFSA Annual Scientific Meeting
-
Cytokinetics Announces Data From Phase 1 Study of CK-4021586
-
Cytokinetics Announces Two Presentations at the 2024 American College of Clinical Pharmacology Annual Meeting
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $52.60
- Day Range
- $51.60–54.16
- 52-Week Range
- $25.98–110.25
- Bid/Ask
- $51.00 / $53.76
- Market Cap
- $6.19 Bil
- Volume/Avg
- 42 / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1,708.89
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 564
- Website
- https://www.cytokinetics.com
Competitors
Valuation
|
Metric
|
CYTK
|
BMY
|
SNY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 7.02 | 12.37 |
Price/Book Value | 56.96 | 6.40 | 1.94 |
Price/Sales | 1,708.89 | 2.35 | 2.76 |
Price/Cash Flow | — | 7.21 | 14.23 |
Price/Earnings
CYTK
BMY
SNY
Financial Strength
|
Metric
|
CYTK
|
BMY
|
SNY
|
|---|---|---|---|
Quick Ratio | 10.28 | 0.94 | 0.52 |
Current Ratio | 10.39 | 1.16 | 1.00 |
Interest Coverage | −6.97 | −3.16 | 8.61 |
Quick Ratio
CYTK
BMY
SNY
Profitability
|
Metric
|
CYTK
|
BMY
|
SNY
|
|---|---|---|---|
Return on Assets (Normalized) | −49.27% | 3.04% | 7.59% |
Return on Equity (Normalized) | — | 11.63% | 14.17% |
Return on Invested Capital (Normalized) | −89.69% | 5.77% | 10.36% |
Return on Assets
CYTK
BMY
SNY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Qxmrznsch | Hzsmq | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Xzrvwwg | Qmkbtx | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Cbbkqzj | Vnkvm | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Glwzgxwpw | Hvlpnf | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Skttwrnf | Szhk | $32.9 Bil | |||
| BioNTech SE ADR
BNTX
| Nzpvfzzk | Rlm | $28.3 Bil | |||
| Moderna Inc
MRNA
| Zqbbyxf | Jwyy | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Jgvcjbd | Vvsxx | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Lhynwtvzm | Jbllps | $13.3 Bil | |||
| Incyte Corp
INCY
| Jpwwrnwl | Wmygjl | $13.0 Bil |
United States